Table 3.
Studies of the PreGen panel in the detection of genetic alterations in fecal samples.
| Authors and references | Markers | Specimen | Specimen n = | Control n = | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| Ahlquist et al. [32] | 15 markers: Kras, APC, p53, BAT26, DIA | CRC Adenoma |
22 11 |
28 | 91% 82% |
93% |
|
| ||||||
| Berger et al. [75] | 19 markers: p523, Kras, APC, BAT26 | CRC | 100 | None | 83% | NA |
|
| ||||||
| Berger et al. [76] | 19 markers: p53, APC, KRAS, BAT26 | Polyps ≥1 cm | 32 | None | 88% | NA |
|
| ||||||
| Tagore et al. [23] | 23 markers: full panel | Advanced CRC | 52 | 212 | 63.5% | 96.2% |
| Adenoma | 28 | 57.1% | ||||
|
| ||||||
| Brand [36] | 23 markers: full panel | CRC | 16 | None | 69% | NA |
|
| ||||||
| Imperiale et al. [77] | 23 markers: full panel | CRC Adenoma |
31 40 |
1423 | 51.6% 32.5% |
94.4% |
|
| ||||||
| Syngal et al. [78] | 23 markers: full panel | CRC Adenoma |
68 23 |
None | 63% 26% |
NA |